女性健康照护市场－全球产业规模、份额、趋势、机会和预测：按药物、应用、地区和竞争格局划分，2021-2031年

全球女性保健市场预计将从 2025 年的 111.2 亿美元成长到 2031 年的 156.9 亿美元，复合年增长率为 5.91%。

该市场涵盖专为治疗、诊断和管理女性特有的生理和生殖系统疾病而设计的药物、医疗设备和诊断服务。推动这一市场成长的关键因素包括慢性病和女性特有疾病的日益普遍，以及女性人口老化导致持续医疗干预需求增加。此外，政府加大对女性健康的投入以及更广泛的保险报销政策也对支撑产业需求和发展发挥着至关重要的作用。

然而，市场扩张面临的主要障碍是开发中国家诊断基础设施和医疗保健服务取得的巨大差距。这种差距限制了关键医疗技术的有效推广，并阻碍了快速增长地区疾病的早期发现。例如，根据美国癌症协会2024年的报告，全球仅有36%的女性接受过子宫颈癌筛检。此类基础设施不足和预防性医疗保健覆盖率低是该领域公平分配和整体发展的重要障碍。

市场驱动因素

政府主导的各项措施和对女性健康的投入不断增加，是推动弥合医学研究和医疗服务领域长期存在的性别差距的关键驱动力。公共部门机构正在启动有针对性的项目，以支持子宫内膜异位症和更年期等疾病解决方案的商业化，并降低早期创新阶段的风险。作为这项努力的象征，美国国防高级研究计划局（DARPA）的医疗部门ARPA-H于2024年10月宣布，已透过其「女性健康衝刺计画」（津贴 for Women’s Health）拨款1.1亿美元，资助23家Start-Ups，以加速从卵巢健康到心血管疾病等领域的研发。联邦政府的这项支持凸显了该领域的重要性，提供了弥合资金缺口所需的必要资金，并确保科学突破能够转化为可实际应用的医疗产品。

同时，女性健康科技和数位健康解决方案的快速发展正在重塑市场格局，它们提供便利、个人化和数据驱动的诊疗路径。这些平台透过实现远距专家咨询和持续监测，正在革新生殖健康、生育治疗和计划生育管理。 2024年10月，Maven Clinic获得1.25亿美元的F轮资金筹措，用于拓展其生育和更年期支持平台。这体现了改善女性健康所带来的经济价值，并因此推动了私人投资的激增。根据2024年世界经济论坛的报告，到2040年，解决女性健康差距问题每年可为全球经济贡献1兆美元。

市场挑战

开发中国家诊断基础设施严重不足，医疗服务取得受限，成为限制全球女性健康市场成长的一大瓶颈。这种结构性缺陷阻碍了医疗产品有效渗透到高需求地区，因为专业药品和诊断设备需要基本的医疗设施才能投入使用。因此，企业在利用这些新兴市场的潜在规模方面面临挑战，本应推动全球扩张的收入来源也停滞不前。

由于缺乏医疗服务，相当一部分女性患者仍未被诊断和治疗，导致潜在市场规模不断萎缩。根据世界经济论坛2024年的数据，由于医疗服务体系的障碍，女性一生中约有25%的时间处于健康状况不佳的状态，而男性则没有这种优势。这项数据凸显了市场机会的巨大损失，并表明无法及时为女性群体提供医疗干预与产业价值的损失和市场发展势头的受阻直接相关。

市场趋势

人工智慧驱动的精准诊断技术的加速发展正从根本上改变市场格局，有效应对筛检准确性和疾病早期检测的关键挑战。传统的诊断框架往往忽略了性别间的生理差异，而开发人员正利用女性专属资料集强化机器学习演算法的训练，以提高乳癌和卵巢癌等疾病的影像诊断灵敏度。这项技术变革对于克服诊断有效性的製度性障碍，引领业界迈向高度个人化的医疗保健至关重要。根据 Lux Capital 2025 年 1 月发布的报告，2024 年全球人工智慧医疗保健市场规模将达到 208 亿美元，但其在女性医疗保健领域的应用仍然有限，这意味着专业诊断解决方案在弥合这一差距方面拥有巨大的发展机会。

同时，随着女性健康科技（Femtech）的范畴扩展至慢性非生殖系统疾病，市场关注点也从不孕不育和怀孕转向解决长期慢性疾病。创新者正迅速开发针对以往未被充分重视、但对女性影响尤为严重的疾病的管理方案，例如自体免疫疾病、心血管疾病和慢性疼痛。这种多元化发展源于迫切需要应对那些限製女性就业和生活品质的健康负担。正如Hologic于2024年12月发布的第四份年度全球女性健康指数报告所指出的，全球超过26%的女性表示存在影响其日常生活的健康问题，这意味着约有10亿女性生活在未得到有效控制的身体机能障碍之中。而这些女性正是这一新兴子部门所关注的治疗对象。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球女性健康市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物特定资讯（EVISTA、XGEVA、Prolia、Mirena、 Zometa、Recrust/Aclarsta、Minastrinn 24 Fe、Nuvaling、Forteo、Premarin、Actonel、ORTHO TRI-CY LO (28)）
  • 依用途分类（荷尔蒙不孕症、停经后骨质疏鬆症、子宫内膜异位症、避孕、更年期症状、卵巢症候群、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美女性医疗保健市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲女性医疗保健市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区女性健康市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲女性医疗保健市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲女性医疗保健市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球女性健康市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• Cardinal Health
• Allergan plc.
• Merck & Co.
• Pfizer Inc.
• Amgen Inc.
• Agile Therapeutics Inc.
• Ferring Pharmaceuticals
• Mylan NV
• Lupin Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Women Healthcare Market is projected to expand from USD 11.12 Billion in 2025 to USD 15.69 Billion by 2031, reflecting a CAGR of 5.91%. This market comprises pharmaceuticals, medical devices, and diagnostic services specifically designed to treat, diagnose, and manage physical and reproductive conditions inherent to women. Key drivers propelling this growth include the increasing prevalence of chronic and gender-specific diseases, alongside an aging female population that requires sustained medical intervention. Additionally, rising government investments in female health initiatives and broader insurance reimbursement policies are playing a fundamental role in supporting industry demand and development.

However, a major obstacle impeding market expansion is the profound disparity in diagnostic infrastructure and healthcare access within developing nations. This gap restricts the effective reach of essential medical technologies and hinders timely disease detection in high-growth regions. For instance, the American Cancer Society reported in 2024 that only 36% of women globally had been screened for cervical cancer. Such infrastructural deficiencies and low rates of preventative care constitute significant barriers to the equitable penetration and overall growth of the sector.

Market Driver

Increasing government initiatives and funding for women's health are serving as critical drivers, effectively mobilizing resources to close historical gender gaps in medical research and care delivery. Public sector agencies are launching targeted programs to de-risk early-stage innovations and support the commercialization of solutions for conditions like endometriosis and menopause. Highlighting this commitment, the Advanced Research Projects Agency for Health announced in October 2024 that it had allocated $110 million to 23 startups through its 'Sprint for Women's Health' awards to accelerate developments in areas ranging from ovarian health to cardiovascular disease. This federal support validates the sector and provides the capital necessary to bridge funding gaps, ensuring scientific breakthroughs become accessible medical products.

Simultaneously, the rapid adoption of FemTech and digital health solutions is reshaping the market by delivering convenient, personalized, and data-driven care pathways. These platforms are revolutionizing the management of reproductive health, fertility, and family planning by enabling remote specialist access and continuous monitoring. In October 2024, Maven Clinic secured $125 million in Series F funding to expand its fertility and menopause benefit platforms, demonstrating the surge in private investment driven by the economic value of improved female health outcomes. According to the World Economic Forum in 2024, addressing the women's health gap could potentially contribute an additional $1 trillion annually to the global economy by 2040.

Market Challenge

The severe disparity in diagnostic infrastructure and limited healthcare access within developing nations creates a substantial bottleneck that specifically curbs the growth of the global women's healthcare market. This structural deficiency hinders the effective penetration of medical products into high-demand regions, as specialized pharmaceuticals and diagnostic devices rely on foundational medical facilities for deployment. Consequently, companies face challenges in capitalizing on the volume potential of these emerging markets, leading to stagnated revenue streams that would otherwise fuel global expansion.

This lack of accessibility results in a significant portion of the female population remaining undiagnosed and untreated, which reduces the effective total addressable market. Data from the World Economic Forum in 2024 indicates that women spent approximately 25% more of their lives in poor health compared to men due to systemic barriers in care delivery. This statistic underscores the magnitude of the missed market opportunity, as the inability to provide timely medical intervention to this demographic directly correlates with lost industry value and suppressed market momentum.

Market Trends

The acceleration of AI-enabled precision diagnostics is fundamentally transforming the market by addressing critical gaps in screening accuracy and early disease detection. While traditional diagnostic frameworks often overlook sex-specific physiological nuances, developers are increasingly training machine learning algorithms on female-specific datasets to improve imaging sensitivity for conditions such as breast and ovarian cancer. This technological shift is essential for overcoming systemic barriers in diagnostic efficacy and moving the industry toward highly individualized care. According to a January 2025 report by Lux Capital, while the global AI healthcare market was valued at $20.8 billion in 2024, its application in women's health remains limited, signaling a massive opportunity for specialized diagnostic solutions to bridge this disparity.

At the same time, the expansion of FemTech into non-reproductive chronic conditions is widening the market's focus beyond fertility and pregnancy to address debilitating long-term illnesses. Innovators are rapidly developing management solutions for autoimmune diseases, cardiovascular health, and chronic pain disorders, which disproportionately affect women yet have been historically under-addressed. This diversification is driven by the urgent need to manage health burdens that restrict female workforce participation and quality of life. As noted in Hologic's December 2024 'Global Women's Health Index Year 4 Global Report', over 26% of women worldwide reported health problems that prevented them from normal daily activities, representing nearly 1 billion women living with unmanaged physical limitations that this expanding sub-sector aims to treat.

Key Market Players

• Bayer AG
• Cardinal Health
• Allergan plc.
• Merck & Co.
• Pfizer Inc.
• Amgen Inc.
• Agile Therapeutics Inc.
• Ferring Pharmaceuticals
• Mylan N.V.
• Lupin Limited

Report Scope

In this report, the Global Women Healthcare Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Women Healthcare Market, By Drug

• EVISTA
• XGEVA
• Prolia
• Mirena
• Zometa
• Reclast/Aclasta
• Minastrin 24 Fe
• NuvaRing
• FORTEO
• Premarin
• ACTONEL
• ORTHO TRI-CY LO (28)

Women Healthcare Market, By Application

• Hormonal Infertility
• Postmenopausal Osteoporosis
• Endometriosis
• Contraceptives
• Menopause
• Polycystic Ovary Syndrome
• Others

Women Healthcare Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Women Healthcare Market.

Available Customizations:

Global Women Healthcare Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Women Healthcare Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, ORTHO TRI-CY LO (28))
  • 5.2.2. By Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Women Healthcare Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Women Healthcare Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Women Healthcare Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Women Healthcare Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Application

7. Europe Women Healthcare Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Women Healthcare Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Application
  • 7.3.2. France Women Healthcare Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Women Healthcare Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Women Healthcare Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Women Healthcare Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Application

8. Asia Pacific Women Healthcare Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Women Healthcare Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Application
  • 8.3.2. India Women Healthcare Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Women Healthcare Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Women Healthcare Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Women Healthcare Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Application

9. Middle East & Africa Women Healthcare Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Women Healthcare Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Women Healthcare Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Women Healthcare Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Application

10. South America Women Healthcare Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Women Healthcare Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Women Healthcare Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Women Healthcare Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Women Healthcare Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cardinal Health
• 15.3. Allergan plc.
• 15.4. Merck & Co.
• 15.5. Pfizer Inc.
• 15.6. Amgen Inc.
• 15.7. Agile Therapeutics Inc.
• 15.8. Ferring Pharmaceuticals
• 15.9. Mylan N.V.
• 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer